SRR23036886
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.430
- INTERFERON_GAMMA_RESPONSE+0.380
- MITOTIC_SPINDLE+0.380
- PROTEIN_SECRETION+0.360
- MTORC1_SIGNALING+0.330
- PI3K_AKT_MTOR_SIGNALING+0.330
- HEME_METABOLISM+0.320
- CHOLESTEROL_HOMEOSTASIS+0.310
- INFLAMMATORY_RESPONSE+0.310
- ALLOGRAFT_REJECTION+0.300
Top 10 suppressed
- MYC_TARGETS_V2-0.300
- ANGIOGENESIS-0.230
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.210
- PANCREAS_BETA_CELLS-0.160
- NOTCH_SIGNALING-0.120
- MYC_TARGETS_V1-0.110
- WNT_BETA_CATENIN_SIGNALING-0.110
- DNA_REPAIR-0.060
- KRAS_SIGNALING_DN-0.040
- MYOGENESIS-0.030
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR23036887 | — | — | 0.843 |
| 2 | 9afe3e00-86a7-4fdb-a253-0bc8896aafe3 | — | — | 0.842 |
| 3 | 8ed1ae0f-90db-445c-9805-f8ae9b55da80 | — | — | 0.812 |
| 4 | TCGA-K4-A6FZ-01A-11R-A31N-07 | — | — | 0.801 |
| 5 | TCGA-CV-7427-01A-11R-2081-07 | — | — | 0.800 |
| 6 | sclcWD9900_S48.txt | — | cohortA1 | 0.798 |
| 7 | SRR8518426 | — | C | 0.793 |
| 8 | TCGA-BT-A0YX-01A-11R-A10U-07 | — | — | 0.788 |
| 9 | b4fd9abd-cb2a-4d1b-abb2-8e2796d009cc | — | — | 0.785 |
| 10 | 71423c68-fae7-472e-b291-a177a0e69538 | — | — | 0.783 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 38 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.430 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.380 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.380 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.360 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.330 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.330 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.320 | Temsirolimus | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.310 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.310 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.300 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.290 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.270 | Idelalisib | — uncovered |
| COMPLEMENT | 0.260 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.260 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.250 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.250 | Inavolisib | — uncovered |
| HYPOXIA | 0.250 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.250 | Idelalisib | — uncovered |
| APOPTOSIS | 0.240 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.230 | Idelalisib | — uncovered |